Drug Discovery– tag –
-
From Beginner to Expert: AI in Drug Discovery – A Definitive Guide from Lab to Market (Part 4: “Antibodies & Biologics × AI”) explores how AI is applied to sequence design, affinity maturation, and developability prediction, and how this differs from small-molecule use cases.
1. Why “Antibodies & Biologics × AI” Is Different from Small Molecules In Part 3, we focused on small-molecule projects. In Part 4, we turn to antibodies and biologics (including antibodies, bispecifics, antibody–drug conjugates, and... -
Oncology Drug Approval News Flash: Daratumumab and hyaluronidase-fihj plus bortezomib, lenalidomide, and dexamethasone approved for newly diagnosed multiple myeloma in transplant-ineligible adults
FDA approval summary On January 27, 2026, the U.S. Food and Drug Administration (FDA) approved daratumumab and hyaluronidase-fihj (Darzalex Faspro, Janssen Biotech, Inc.) in combination with bortezomib, lenalidomide, and dexamethasone (V... -
From Beginner to Expert: AI in Drug Discovery – A Definitive Guide from Lab to Market (Part 3: “Small Molecules × AI”) walks through how AI is actually used from hit finding to lead optimization, highlighting concrete use cases, benefits, and limitations.
1. Why Small Molecules Became the Primary Testbed for AI When you scan AI-in-drug-discovery papers and case studies, the first thing you notice is how many of them focus on small molecules. This is not just because small-molecule R&D... -
The Word “Vaccine” Breaks the Conversation: How Far Have Cancer Vaccines Actually Come?
The moment the word “vaccine” appears, conversations tend to heat up—and then collapse. This happens in infectious disease, and it also happens in cancer.In most cases, the problem is not a lack of knowledge. The problem is structural: w... -
From Beginner to Expert: AI in Drug Discovery – A Definitive Guide from Lab to Market (Part 2: “Data and Algorithms Behind AI-Driven R&D”) explains which data types AI relies on, what sources those data come from, and how representative model families are used in practice.
1. Data and Models: The Core of AI in Drug Discovery In Part 1, we mapped where AI can plug into the drug discovery and development value chain and what it can – and cannot – do. In Part 2, we zoom in on the foundations: data and models.... -
From Beginner to Expert: AI in Drug Discovery – A Definitive Guide from Lab to Market (Part 1: “What Is AI in Drug Discovery?”) maps the entire R&D-to-market value chain and clarifies what AI can – and still cannot – do.
1. Why AI in Drug Discovery Is in the Spotlight Now “AI in drug discovery” has become a buzzword in recent years, but it is not a magic technology that appeared overnight. Traditional in silico approaches – QSAR, docking, and statistical... -
JPM2026 Key Topics Series Part 3: How to Read CEO Remarks — Companies That Speak With Numbers vs. Companies That Signal Posture
At JPM2026, CEO remarks drew outsized attention. The reason is straightforward: professional investors already track patent cliffs, revenue concentration, and forward sales trajectories. What they want from JPM is not “nice words,” but a... -
JPM2026 Key Topics Series Part 2: Why Mega-M&A Didn’t Show Up — Yet Capital and Deals Still Moved
One of the defining “feelings” at JPM2026 was that the conference was crowded and energetic—yet true mega-M&A headlines were scarce. That is not an anomaly. It reflects a structural optimization driven by today’s capital costs, integ... -
JPM2026 Key Topics Series Part 1: Obesity & Metabolic (GLP-1) — The Battle Has Moved to Execution
At JPM2026, obesity and metabolic disease (GLP-1) remained the gravitational center of the conference. Yet the most decisive conversations were not about incremental clinical deltas or “which molecule is best.” The battleground has shift... -
Women’s Cancer Risk Across the Life Course: Hormones, Milestones, and Practical Prevention (Series Hub)
This series places women’s cancer risk on a single life-course map—from puberty and reproductive years to pregnancy/childbirth, the menopause transition, and postmenopause. We align breast, ovarian, and endometrial cancer considerations ... -
Series: Women’s Cancer Risk Across the Life Course: Hormones, Milestones, and Practical Prevention (Episode 7)
Episode 7 | A Life-Course Prevention Playbook: Think in Life Events, Not Just Age—When to Seek Care, Screening Principles, and a Practical Summary Across this series, we placed breast, ovarian, and endometrial cancer risk on the same lif... -
Series: Women’s Cancer Risk Across the Life Course: Hormones, Milestones, and Practical Prevention (Episode 6)
Episode 6 | Lifestyle and Women’s Cancer Risk: Weight, Activity, Alcohol, and Sleep—A Practical Plan to Lower Risk Without Chasing Perfection Hormonal milestones (menarche, pregnancy, menopause) shape women’s cancer risk over decades. Li... -
Series: Women’s Cancer Risk Across the Life Course: Hormones, Milestones, and Practical Prevention (Episode 5)
Episode 5 | Perimenopause and Menopausal Symptoms: Balancing Cancer Risk, Quality of Life, and the Role of HRT Menopause is often described as “estrogen going down,” but lived experience is usually about something else: fluctuation. Hot ... -
Series: Women’s Cancer Risk Across the Life Course: Hormones, Milestones, and Practical Prevention Episode 4
Episode 4 | Endometrial Cancer, Hormone Balance, and Metabolic Health: The “Unopposed Estrogen” Intersection “My hormones feel off” is a common phrase—useful, but often too vague to drive action. Endometrial cancer (cancer of the uterine... -
Series: Women’s Cancer Risk Across the Life Course: Hormones, Milestones, and Practical Prevention Episode 3
Episode 3 | Ovarian Cancer: The “Silent Killer,” Reproductive Aging, and Why Detection Is Hard Ovarian cancer is sometimes called a “silent killer.” That phrase gained traction for two reasons: early symptoms are often not obvious, and t... -
Series: Women’s Cancer Risk Across the Life Course: Hormones, Milestones, and Practical Prevention Episode 2
Episode 2 | Breast Cancer Across Life Stages: Reading Risk Calmly with “Relative vs Absolute” Breast cancer is one of the most information-heavy topics in women’s health. Because it appears frequently in news and social media, it is also... -
Series: Women’s Cancer Risk Across the Life Course: Hormones, Milestones, and Practical Prevention Episode 1
Episode 1 | A Life-Course Map of Female Hormones: From Puberty to Post-Menopause Women’s health topics are often discussed in separate “boxes”: symptoms (PMS, menstrual pain, menopause) on one side, and diseases (breast cancer, ovarian c... -
From Beginner to Expert | ADC: From Basics to the Frontline – A Deep Dive into the Global ADC Land Grab and Beyond Column B – A Practical ADC Strategy Checklist: Ten Questions for Pharma, Biotechs, Investors, and Advisors
In Column B, we translate the themes of this series into a practical checklist for people who must make decisions about ADCs in their daily work: executives and R&D / BD leaders at pharma companies, biotechs and start-ups developing ... -
From Beginner to Expert | ADC: From Basics to the Frontline – A Deep Dive into the Global ADC Land Grab and Beyond Column A – How Enhertu Reshaped the ADC Landscape: A Case Study in Design, Clinical Strategy, and Business Impact
In Column A, we focus on Enhertu, the ADC that appears repeatedly throughout this series, and ask a simple but far-reaching question:Why did this particular ADC become such a central reference point in the current ADC land grab? We will ... -
From Beginner to Expert | ADC: From Basics to the Frontline – A Deep Dive into the Global ADC Land Grab and Beyond Part 7 – Synthesis: Where We Stand in 2025 and How ADCs May Evolve Toward the 2030s
In Part 1, we explored why the ADC land grab is happening now and how ADCs fit into the broader oncology landscape.In Part 2, we reviewed ADC design—antibody, payload, linker, conjugation—and discussed what people mean by first-, second-...
